May 4, 2018
An Investigational New Drug (IND) sponsored by a corporate entity is considered as a ‘Commercial IND.’ Center for Drug Evaluation and Research (CDER) has the authorization to designate IND as commercial if it finds the intent to commercialize the drug in future. In the United States, INDs must be registered with the Food and Drug Administration (FDA). As part of the implementation of FDA’s final notification released on May 5th, 2015 regarding adaption of eCTD formats, Commercial INDs are required to be submitted in eCTD format by May 5, 2018.